VOR-101 / Voro Therapeutics - LARVOL DELTA

Tumor-activated PrimeBody biologics platform enables more potent CD47 targeting and superior therapeutic index in preclinical models (AACR 2026) - "Consequently, VOR-101 achieves >700-fold tumor-to-serum selectivity, a major improvement over the <25-fold selectivity observed with benchmark linkers currently in clinical development.In a translational hCD47/hSIRPα mouse model, magrolimab induced 50-60% depletion of red blood cells (RBCs) and exhibited poor systemic exposure (~10 nM). In xenograft models, VOR-101 induced durable complete responses that persisted well beyond the dosing period.Together, these findings demonstrate that VOR-101 (a tumor-activated, Fc-enhanced, high-affinity CD47 blocker) significantly improves the therapeutic index in preclinical models compared to clinical comparators. VOR-101 is advancing through IND-enabling studies with potential to exhibit single-agent activity in solid tumors."

Preclinical • Oncology • Solid Tumor • CD47 • SIRPA